In summary, the cooperative regulation of NSCLC cells by nAChRs and β-ARs and the strong inhibiting effects of propranolol at several levels of these pathways identify agents that interfere with this regulatory cascade as promising new tools for marker-guided prevention and adjuvant therapy of a subset of NSCLCs. The gene discussed is CTBP1; the disease is non-small cell lung carcinoma.